US EditionPublished • loading... • Updated
OS Therapies Advances Osteosarcoma Treatment Toward Regulatory Submissions Following Strong Clinical Data – citybuzz
Summary by citybuzz.co
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
OS Therapies Advances Osteosarcoma Treatment Toward Regulatory Submissions Following Strong Clinical Data – citybuzz
OS Therapies Inc. has advanced key clinical and regulatory milestones for its lead asset OST-HER2, positioning the company for potential regulatory submissions in both the United States and United Kingdom by early 2026. The company reported final two-year overall survival data from its 41-patient Phase 2b trial showing a 75% survival rate for patients treated with OST-HER2 compared to 40% in historical controls, with 100% two-year survival among…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
